Read our latest updates & insights

Significant biosimilar activities this week include

11 May 20 | Healio reported on a new study comparing faricimab to ranibizumab which was presented at a virtual meeting of the Association for Research in Vision and Ophthalmology. The presenters announced that faric...

JHL Biotech announces that the first group of subjects in the Australian randomised Ph I trials of JHL1266 (proposed denosumab) have been dosed.

Samsung Bioepis announces 24-week interim results from a Ph III trial of SB11 (a proposed ranibizumab biosimilar) in patients with neovascular age-related macular degeneration. Samsung Bioepis announced that the primary endpoints of the trial were met, suggesting that SB11 ...

Formycon releases an update on its biosimilar portfolio. Ph III clinical trials for a proposed ustekinumab biosimilar are scheduled to commence in Q3 2020.

Samsung Bioepis announces the results of a four year follow up study of Ontruzant® (trastuzumab) will be presented at the ASCO20 Virtual Scientific Program organized by the American Society of Clinical Oncology (ASCO) at the end of this month. The study assessed the cardiac...

Formycon releases an update on its biosimilar portfolio. In the statement, Formycon confirmed it is continuing to work with license partner Bioeq on a resubmission of the BLA for FYB201 (proposed ranibizumab biosimilar).

Formycon releases an update on its biosimilar portfolio, announcing its biosimilar aflibercept candidate is proceeding as expected, with Ph III clinical trials expected to begin mid-2020.

Biocon Biologics receives good manufacturing practice compliance certificate from the EMA for Bengaluru facilities.

Alvotech releases the results of two studies for AVT02, a proposed adalimumab biosimilar, announcing both studies met their primary endpoints. Alvotech announced that the Ph I clinical study demonstrated the PK similarity of AVT02 to the reference product Humira®, while the...

Significant biosimilar activities this week include

01 May 2020 | AbbVie released its Q1 2020 financial results, reporting a 13.7% increase in US sales of Humira® (adalimumab) from Q1 2019. In global markets, Humira® sales were down 14.9%, a decline that was attribut...